IDH2 and acute myeloid leukemia: ND AML patients treated with VEN + AZA demonstrated 66.4% composite complete remission rate (CRc) [complete remission (CR) or complete remission with incomplete hematologic recovery (CRi)] and a median OS of 14.7 months, with particularly favorable outcomes in those harboring isocitrate dehydrogenase 2 (IDH2) gene mutations [5].